News FDA rejects Sunovion's nebulised COPD drug The US regulator has rejected Sunovion’s nebulised therapy for chronic obstructive pulmonary disease (COPD), leaving the company struggling to stay ahead of rivals.
News European regulators back Chiesi COPD triple therapy Chiesi takes on Seretide and other lung drugs with Trimbow.
News GSK gets short term boost as second US Advair generic reject... FDA rejects Hikma drug, regulator has "major" issue with Mylan's rival.
News GSK’s Relvar Ellipta comes out on top in real world study Encouraging results will support growth of its next generation respiratory treatment
News AZ hopes to boost respiratory pipeline with Pieris deal AstraZeneca is hoping to boost its respiratory pipeline in a deal potentially worth more than $2 billion with US biotech Pieris Pharmaceuticals.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
